Evercore ISI Reaffirms Their Buy Rating on Dynavax (DVAX)
In a report released today, Jonathan Miller from Evercore ISI maintained a Buy rating on Dynavax, with a price target of $16.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Miller covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Intellia Therapeutics, and Dynavax. According to TipRanks, Miller has an average return of -4.5% and a 50.00% success rate on recommended stocks.
In addition to Evercore ISI, Dynavax also received a Buy from TD Cowen’s Phil Nadeau in a report issued today. However, on October 21, TR | OpenAI – 4o reiterated a Hold rating on Dynavax (NASDAQ: DVAX).
Based on Dynavax’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $95.44 million and a net profit of $18.72 million. In comparison, last year the company earned a revenue of $73.8 million and had a net profit of $11.39 million
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is neutral on the stock. Most recently, in August 2025, Scott Dunseth Myers, a Director at DVAX bought 3,800.00 shares for a total of $41,116.00.
Read More on DVAX:
Disclaimer & DisclosureReport an Issue
- Dynavax’s Promising Growth and Strategic Initiatives Justify Buy Rating with $25 Target
- Dynavax reports Q3 EPS 21c vs. 12c last year
- Dynavax enters license agreement for Vaxart’s oral COVID-19 vaccine program Vaxart
- Dynavax Technologies (DVAX) Q3 Earnings Cheat Sheet
- Dynavax Technologies Advances in Pneumonic Plague Vaccine Study
